F. Roitberg
0000-0003-2546-543X
13 papers found
Refreshing results…
Adapting Cancer Civil Society Organizations to Accelerate COVID-19 Vaccinations in People Living With Cancer in Low- and Middle-Income Countries—A Commentary
Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey
Thyroid collision tumor containing oncocytic carcinoma, classical and hobnail variants of papillary carcinoma and areas of poorly differentiated carcinoma
Tracking the Workforce 2020-2030: Making the Case for a Cancer Workforce Registry
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
Impact of Strategies for Mitigating Delays and Disruptions in Cancer Care Due to COVID-19: Systematic Review
Delays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review
Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System
In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments
Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer
Regulatory Approval for Oncology Products In Brazil: A Comparison Between The Fda And Anvisa Approval Timelines
1500 Long term toxicities after cisplatin-based concurrent chemoradiation in head & neck squamous cell carcinoma (HNSCC) disease-free patients: A cross-sectional study
Missing publications? Search for publications with a matching author name.